Immunotherapy with Tacrolimus (FK506) Does Not Select for Resistance to Calcineurin Inhibitors inCandida albicansIsolates from Liver Transplant Patients
- 1 April 2006
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (4) , 1573-1577
- https://doi.org/10.1128/aac.50.4.1573-1577.2006
Abstract
In Candida albicans, calcineurin mediates tolerance to azole antifungal drugs, survival in serum, and virulence. In this study, we examined 24 Candida isolates from liver transplant recipients receiving a calcineurin inhibitor as a component of their immunosuppressive therapy. We were unable to detect a difference in susceptibility to calcineurin inhibitors in combination with fluconazole, serum, or calcium in these isolates.Keywords
This publication has 35 references indexed in Scilit:
- Calcineurin Is Required forCandida albicansTo Survive Calcium Stress in SerumInfection and Immunity, 2005
- Calcineurin Is Essential for Candida albicans Survival in Serum and VirulenceEukaryotic Cell, 2003
- Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study1Transplantation, 2003
- Calcineurin is essential for survival during membrane stress in Candida albicansThe EMBO Journal, 2002
- TRENDS IN INVASIVE FUNGAL INFECTIONS IN LIVER TRANSPLANT RECIPIENTSTransplantation, 2002
- Selection ofCandida glabrata strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasisEuropean Journal of Clinical Microbiology & Infectious Diseases, 1997
- Invasive Fungal Infections in Liver Transplant Recipients Receiving Tacrolimus as the Primary Immunosuppressive AgentClinical Infectious Diseases, 1997
- Identification of calcineurin as a key signalling enzyme in T-lymphocyte activationNature, 1992
- FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurinNature, 1992